Stem Cell Center of Competence ::: Uni Basel, Switzerland
 

 
    Search    
 
  Research
     
 
   
 
 


 
 

 
   

back

   

Home > Research > Topics > T. Bouwmeester


 

Dr. Tewis Bouwmeester

 
 

Dr. Tewis Bouwmeester
Developmental Molecular Pathways (DMP)
Novartis Institutes for Biomedical Research (NIBR)
Novartis Pharma AG
Forum 1, Novartis Campus
CH-4056 Basel / Switzerland

 
E-mail tewis.bouwmeester
@novartis.com
Phone +41 61 324 41 29
Fax +41 61 324 76 55
 
Homepage
 
 

Tewis Bouwmeester is Senior Unit Head in the Department of Developmental and Molecular Pathways (DMP) at the Novartis Institutes for Biomedical Research (NIBR) in Basel. He is a trained developmental biologist working in the field of regenerative medicine. His group is part of a regenerative medicine initiative to identify low molecular weight compounds and/or secreted factors that can activate adult tissue stem/progenitor cells such as intestinal crypt cells and hematopoietic precursors to regenerate damaged and/or aged tissues. In addition, he has an interest in dissecting the mechanisms of lineage restriction by identifying compounds (stem cell differentiators) that can drive embryonic stem cells into a defined somatic lineage. His group has core expertise in “state of the art” quantitative proteomics technologies to: i) dissect regulatory protein-protein interactions in vivo, ii) identify and quantify post translational modifications such as phosphorylation and iii) to monitor global proteome changes in response to growth factors and/or upon lineage commitment.

For additional details, see http://www.nibr.com

Original publications

  • Bouwmeester T,* Bauch A, Ruffner H, et al. (2004). A physical and functional map of the human TNFa/NF-kB signal transduction pathway. Nature Cell Biol. 6:97-105.
    *corresponding author.
  • Gavin A-C, Aloy P, Grandi P, Krause R, et al. (2006). Proteome survey reveals modularity of the yeast cellular machinery. Nature 30:631-636.

  • Bantscheff M, Eberhard D, Abraham Z, et al. (2007). A quantitative chemical proteomics approach reveals novel modes of action of clinical Abl kinase inhibitors. Nature Biotech. 25:1035-1044.

  • Huang SM. et al. (2009). Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461:614-620.

 




 
 
 
           
     
       Copyright © 2010 BSCN